Questions
What is CRISPR in simple terms?
Doudna describes it as a technology for editing the code of life, letting scientists make precise changes to individual genes. Milken compared it to a spell check for genetics, and she said she liked the analogy.
How is CRISPR being used against COVID-19?
Doudna says it provides faster, cheaper, higher-volume testing than earlier technologies. Her institute's lab has tested well over 100,000 clinical samples, including for people with little access to testing.
Could CRISPR cure inherited diseases and cancer risk soon?
Not soon, according to Doudna. She expects it to become increasingly possible over coming decades, and says doctors still need to solve how to deliver the editing inside a patient's body.
What is the idea of proactive gene editing for heart disease?
Doudna describes using editing to give people a protective gene that a few lucky people inherit naturally, which protects against high cholesterol and heart disease. She suggests spreading it through the population could be huge.
How can ordinary people support or learn about this work?
Doudna points to the institute's website, innovativegenomics.org, its Ask a Scientist forum, and its slide decks and videos. She also welcomes philanthropic and company partnerships.
Facts
Stated by the speakers. Each quote matches the transcript, which shows what was said, not that it is true.
Jennifer Doudna helped develop CRISPR-Cas9 in 2012, a technology for precisely editing gene sequences in microorganisms, plants and animals.
“In 2012, she helped develop the breakthrough CRISPR-Cas9 technology, which enables the precise editing of gene sequences in microorganisms, plants, and animals.”
0:00:24 · Speaker 3 · CRISPR-Cas9 · 2012
Jennifer Doudna founded the Innovative Genomics Institute at UC Berkeley in 2014.
“the Innovative Genomic Institute at UC Berkeley, which you founded in 2014.”
0:04:06 · Mike Milken · Institute founding · 2014
The Innovative Genomics Institute is based at the University of California, Berkeley, in partnership with the University of California, San Francisco.
“I'm excited to have an institute established now at the University of California, Berkeley, and in partnership with the University of California, San Francisco”
0:04:40 · Jennifer Doudna · Institute partnerships
The Innovative Genomics Institute set up a clinical COVID testing lab in three weeks in early 2020 and published a guide to doing so.
“the IGI was able to institute a clinical testing lab in three weeks, we got a pop up lab going, and we've published how to do that.”
0:05:22 · Jennifer Doudna · COVID testing lab · 2020
The Innovative Genomics Institute's testing lab had processed well over 100,000 clinical samples for COVID-19 by the time of this interview.
“since then, we've now tested well over 100 ,000 clinical samples for COVID-19 diagnosis.”
0:05:53 · Jennifer Doudna · COVID testing · 2020
The Innovative Genomics Institute worked with community health groups to provide COVID testing to people in homeless encampments, nursing homes and frontline jobs who would otherwise lack access.
“So this means people living in homeless encampments, nursing homes, and many frontline workers.”
0:05:53 · Jennifer Doudna · Community testing · 2020
The Innovative Genomics Institute routinely tests police, fire support personnel and California Energy Commission workers for COVID-19.
“So we routinely now test our our police, our fire support personnel, California Energy Commission, the people keeping the lights on around the state of California.”
0:05:53 · Jennifer Doudna · Frontline testing · 2020
The Moderna and Pfizer COVID-19 vaccines use mRNA technology, which was new for vaccines.
“Two of the early vaccines are the Moderna vaccine and the Pfizer that use mRNA technology, a new technology for vaccines.”
0:06:53 · Mike Milken · mRNA vaccines · 2020
Doudna noted that two RNA-based COVID-19 vaccines looked highly effective in early studies within about a year of the virus becoming known.
“it's extraordinary to think that a year ago, we didn't even know about this virus, And now we have two different RNA-based vaccines that look highly effective in these early studies.”
0:07:56 · Jennifer Doudna · Vaccine speed · 2020
Doudna attributed the speed of the RNA vaccines to earlier academic and company research on RNA as a delivery vehicle that induces an immune response.
“Because of fundamental research that was done years ago in an academic setting and then later in companies to develop RNA as a delivery vehicle, and it's very effective in inducing an immune response.”
0:07:56 · Jennifer Doudna · RNA research
Doudna said the sequence of the entire human genome has been available for about two decades.
“We have the sequence of the entire human genome now that's been available for the last two decades.”
0:03:13 · Jennifer Doudna · Human genome
Milken said more than 50% of all economic growth over the last two centuries has come from advances in public health and medical research.
“more than 50 % of all economic growth has come from advances in public health and medical research for the last two centuries.”
0:08:49 · Mike Milken · Economic growth
Milken said philanthropy provides about 3% of life-science research funding, with the rest coming from companies and governments.
“Philanthropy today makes about 3 % of what goes on on research and biosciences, life sciences, between for-profit companies and governments.”
0:10:03 · Mike Milken · Research funding
The Innovative Genomics Institute holds an annual visitor's day where people of all ages can learn about its work.
“we have a visitor's day every year where we welcome people of all ages to come in and talk to us, find out who we are, what we're doing, and give us feedback.”
0:09:17 · Jennifer Doudna · Public outreach
Doudna described the idea of using genome editing to give people a protective gene that some lucky people inherit naturally, which protects against high cholesterol.
“The idea that one could use genome editing to give all of us a protective gene that is known to, and a few lucky people that inherit this naturally, have a protection against high cholesterol.”
0:14:20 · Jennifer Doudna · Cardiovascular editing
Doudna cautioned that correcting BRCA1 mutations to protect against breast cancer is not a year away.
“I don't want people to come away from this conversation thinking that we're a year away from being able to correct BRCA1 mutations in people that would give them protection against breast cancer, for example.”
0:14:55 · Jennifer Doudna · BRCA1 editing
Doudna said a key need is to deploy CRISPR inside patients' bodies, called in situ, rather than editing cells in a lab and returning them.
“we do need to figure out how to deploy CRISPR in clinical settings to patients in situ, meaning in their body, without having to take cells out to do the editing in the lab and then put them back.”
0:15:31 · Jennifer Doudna · In situ delivery
In 2011, Milken held a three- to four-day event at Lake Tahoe with about 80 to 90 people from varied backgrounds to discuss accelerating innovation.
“in 2011, we put on an event and we brought about 80 to 90 people from varied backgrounds to Lake Tahoe to sit down for three or four days.”
0:16:21 · Mike Milken · Lake Tahoe event · 2011
Milken said the National Center for Advancing Translational Sciences became a new center at the National Institutes of Health, funded by the U.S. government at $500 to $600 million a year for 10 years.
“NCATS, National Center for Advancing Translational Science that became a new center at the NIH, and the U.S. government agreed to fund for $500 to $600 million a year for 10 years.”
0:16:21 · Mike Milken · NCATS funding · 2011
Milken said Chris Austin was the first head of NCATS and still held the role at the time of the interview.
“And Chris Austin was the first head of the center and still is today.”
0:16:21 · Mike Milken · NCATS leadership
Milken said FasterCures had interacted with almost 190 to 200 disease-specific foundations and helped launch many of them.
“Faster Cures has interacted with almost 190 to 200 and helped launch many of them”
0:16:56 · Mike Milken · Disease foundations
Doudna said the Innovative Genomics Institute places plant biologists next to researchers working on T cell therapies, which produced useful exchange of ideas.
“You might not have expected that there would be obvious value in having plant biologists working right next door to people that are doing T cell therapies.”
0:18:28 · Jennifer Doudna · Interdisciplinary research
Doudna said Berkeley has no medical school, yet the Innovative Genomics Institute could build a clinical lab because of its staff and infrastructure and its work with regulators.
“We don't have a medical school. Why were we able to do that? Honestly, it was because we had the staff and the infrastructure at the IGI”
0:19:43 · Jennifer Doudna · Clinical lab · 2020